Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans

Journal of Nuclear Medicine

Volumn 48, Issue 9, 2007, Pages 1449-1458

  Francis, Roslyn J ^a   Byrne, Michael J ^a   Van Der Schaaf, Agatha A ^a   Boucek, Jan A ^a   Nowak, Anna K ^a,b   Phillips, Michael ^c   Price, Richard ^a   Patrikeos, Andrew P ^a   Musk, A William ^a   Millward, Michael J ^a,b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

18F FDG PET; Chemotherapy; Mesothelioma; Response

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SURVIVAL RATE;

EID: 34548552737     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.042333     Document Type: Article

References (28)

1. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257-260.
2. Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87:491-496.
3. Nowak AK, Stockler MR, Byrne MJ. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. J Clin Oncol. 2004;22:3172-3180.
4. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101-2111.
5. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065.
6. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651-2657.
7. 18F-FDG PET. J Nucl Med. 2005;46:1144-1150.
8. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998;114:713-722.
9. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med. 1999;40:1241-1245.
10. Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003;126:11-16.
11. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med. 2006;47:1059-1066.
12. Keyes JW. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836-1839.
13. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994;35:1308-1312.
14. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations - European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782.
15. Kwek BH, Aquino SL, Fischman AJ. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest. 2004;125:2356-2360.
16. Green AJ, Baig S, Francis RJ, Begent RHJ. Semi quantitative analysis of F18-FDG imaging using a hybrid camera for the assessment of tumor response to therapy [abstract]. Eur J Nucl Med. 2001;28(suppl):S132.
17. Boucek J, Francis RJ, Green AJ. Automated approach to identification and quantitation of tumour volumes in chemotherapy monitoring using FDG PET [abstract]. J Nucl Med. 2005;46(suppl):464P.
18. Armato SG III, Oxnard GR, MacMahon H, et al. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys. 2004;31:1105-1115.
19. Steinert HC, Santos Dellea MM, Burger C, Stahel R. Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging. Lung Cancer. 2005;49:S33-S35.
20. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18:1676-1688.
21. Maisey NR, Webb A, Flux GD, et al. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer. 2000;83:287-293.
22. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol. 1995;13:1470-1477.
23. Flamen P, Van CE, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002;13:361-368.
24. Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159-171.
25. Guillem JG, Moore HG, Akhurst T, et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg. 2004;199:1-7.
26. 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med. 2002;43:1667-1673.
27. 18F]fluorodeoxyglucose. J Clin Oncol. 2006;24:4587-4593.
28. van Klaveren RJ, Aerts JG, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer. 2004;43:63-69.